AT101
/ IngenOx Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 12, 2023
Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-β signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors.
(PubMed, Cell Death Dis)
- "Ectopic overexpression of Btg2 inhibited the EMT response, blocking cell migration, and promoted cancer cell death. These data demonstrate that the combination therapy of T1-44 with Vactosertib is synergistic for pancreatic cancer, suggesting that this novel combination therapy has value in the treatment strategy of patients with pancreatic cancer."
Journal • Preclinical • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • BTG2 • PRMT5 • TGFB1
1 to 1
Of
1
Go to page
1